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Abstract
Previous epidemiological cohorts demonstrated that higher body mass index (BMI) 
was associated with greater survival in patients treated by hemodialysis. Although BMI 
is a simple measure of adiposity in general population, it may be an inaccurate indicator 
of nutritional status, particularly among dialysis patients given that it does not differen-
tiate between muscle mass and fat as well as body fat distribution. This problem might 
be aggravated in end-stage renal disease patients because of wasting or edema. In addi-
tion, individuals with higher BMI usually have both higher muscle and fat mass than 
those with lower BMI. Therefore, more sophisticated tool of body composition analysis 
is needed to address the query of which component is associated with mortality out-
come among patients receiving hemodialysis. We summarized the current state of body 
composition, including lean and fat tissue evaluated by bioelectrical impedance analysis, 
dual X-ray absorptiometry, computerized tomography, or magnetic resonance imag-
ing, and its association with clinical outcomes among hemodialysis patients. The studies 
using anthropometry for the estimation of muscle mass, either mid-arm muscle circum-
ference as a proxy of muscle mass or skinfold thickness and waist circumference as a sur-
rogate of body fat and visceral fat, respectively, were all included in this review.
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1. Introduction
Dialysis-related malnutrition is prevalent among end-stage renal disease (ESRD) patients 
and may have important implications for mortality and other outcomes [1]. Various metabolic 
derangements occur during hemodialysis such as increased pro-inflammatory state, chronic 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Creat ve
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metabolic acidosis, and accumulation of uremic toxins that can negatively impair body protein 
anabolism and increase the rate of muscle degradation [2, 3]. In fact, the term “malnutrition” 
has been recently replaced by “wasting” in recognition that this disorder might not be cor-
rected by appropriate supplementation of dietary intake. Consequently, the International 
Society of Renal Nutrition and Metabolism defined the term “protein energy wasting” (PEW) 
according to the presence of at least three out of the following four criteria: (1) abnormal low 
levels of serum albumin, prealbumin, or cholesterol concentrations; (2) low body mass or fat 
mass; (3) decreased muscle mass; and (4) inadequate protein or energy intake for more than 2 
months with or without abnormal nutritional score [4]. However, individual with low muscle 
mass can be misclassified as not having PEW if there is a concurrently increase in non-muscle 
body weight, making a diagnosis of nutritional disorder difficult in such case.
While kidney disease wasting remains a concerning issue, obesity or excess body adiposity is 
also a debatable topic among dialysis community. Although increased body mass index (BMI) 
is one of the most common cardiovascular risk factors and other health problem-related risks 
in general population, some studies have reported that a low, rather than high, body fat is 
an independent predictor for poor survival in maintenance hemodialysis patients [5, 6]. One 
potential explanation is that although BMI is a key nutritional assessment tool recommended 
by both the Kidney Disease Outcomes Quality Initiative (KDOQI) [7] and European guidelines 
[8], it may not be a good representative of body fatness and cannot reflect the real nutritional 
status particularly in patients treated by hemodialysis [9].
This chapter aims to provide an updated current evidence describing the significance of body 
composition as a useful nutritional tool to detect as well as monitor the important outcomes 
associated with patients undergoing hemodialysis.
2. Body composition and its clinical outcomes among hemodialysis 
patients
2.1. Role of body mass index as a nutritional parameter in hemodialysis patients
BMI is defined as body weight in kilograms divided by the square of height in meters. BMI 
is currently considered as a useful nutrition risk stratification tool for obesity in the general 
population and undernutrition in developing countries because of its simplicity and ease of use 
[10]; however, its accuracy to assess the nutritional status in chronic kidney disease (CKD) 
patients is still questionable [11]. Observational studies have reported contradictory findings 
regarding the association between obesity and mortality in CKD population. Previous epide-
miological studies in hemodialysis patients have demonstrated that patients with low BMI are 
at higher risk of mortality than those with normal BMI range, whereas high BMI is not associ-
ated with higher mortality as it is in general population, the phenomenon known as “obe-





Obese individual with higher BMI usually has not only higher body fat, but also higher muscle 
mass, therefore which component of body composition-fat or lean-is more associated with sur-
vival is debatable topic since then. Other studies have suggested a U- or J-shaped association 
between obesity classified by BMI and mortality among dialysis patients, with a higher risk 
of death in underweight and morbidly obese categories compared with normal weight [18, 19]. 
Recently updated meta-analysis [20] has shown that for every 1 kg/m2 increase in BMI, there 
was a reduction in the risk of all-cause and cardiovascular mortality by 3% (hazard ratio (HR) 
0.97; 95% confident interval (CI) 0.96–0.98) and 4% (HR 0.96; 95% CI 0.92–1.00), respectively, 
in CKD stage 5 undergoing hemodialysis, whereas a similar association between BMI and risk 
of death was not observed in patients on peritoneal dialysis. Interpretation of these data should 
be aware of other limitations of using BMI as a single nutritional assessment tool among that 
population.  Inaccuracy  of  measurement  and  misclassification  may  exist,  causing  an  over-
representation of individual with lower cardiovascular disease risk in higher BMI categories 
and inflating the observed protective effects in obese hemodialysis patients. In addition, BMI 
may underestimate the prevalence of obesity in ESRD population. A previous study among 
dialysis patients from Stockholm [21] found that obesity diagnosis using BMI cut point mis-
classified more than half of the patients with excess body fat as having normal BMI. This data 
emphasized the limitation of BMI as a reflection of body composition, and a BMI of more than 
or equal to 30 kg/m2 has a high specificity but low sensitivity for excess body fat. In agreement 
with the Swedish cohort, analyses in prevalent hemodialysis patients from the United States 
Renal  Data  System  (USRDS)  database  found  that  underidentification  of  obesity  was more 
common by using BMI than waist circumference criteria (31.3% vs 15.2%, respectively) [22]. 
Furthermore, the agreement level of obesity by BMI was significantly lower than waist circum-
ference (Cohen kappa of 0.4 vs 0.6, p < 0.01) compared to the reference standard (percent body 
fat criteria), highlighting the poor performance of BMI for excess adiposity. Moreover, BMI 
does not capture the differentiation in body fat distribution between subcutaneous and central 
fat deposit, which is more associated with inflammation, oxidative stress,  insulin resistance, 
and so on [23, 24]. Lastly, extracellular volume expansion and fluid overload could probably 
yield falsely high BMI [25, 26].
Previous studies have shown that changes in body weight are more strongly associated 
with mortality than measurement of BMI at a single time point. Database from a large hemo-
dialysis organization and the Scientific Registry of Transplant Recipients [27] revealed that 
patients with body weight loss of 3–5 kg and more than 5 kg had death hazards of 1.31 (95% 
CI 1.14–1.52) and 1.51 (95% CI 1.30–1.75), respectively, compared to those with minimal 
weight change (±1 kg) over the past 6 months. However, one of the limitations is that poten-
tial reasons of weight change could not be  identified due to  its observational nature, mak-
ing confounded by intercurrent health status likely as more spontaneous weight loss among 
sicker patients. The Current Management of Secondary Hyperparathyroidism: A Multicenter 
Observational Study (COSMOS) [28] also evaluated the implication of weight loss and gain 
among obese patients undergoing hemodialysis and their nonobese counterparts. Assuming 
that weight changes were unintentional, weight loss (<1% of dry weight at baseline) was sig-
nificantly associated with increased rate of mortality, whereas weight gain (>1%) was strongly 
associated with higher survival compared with stable weight (±1%). Interestingly, the asso-
ciations of weight variation and death were attenuated after stratification by BMI categories. 





0.59–1.62) among obese  individual. These data  raise attentions  to  rapid weight differences 
as a potential clinical sign for health monitoring in hemodialysis patients.
On this basis, recent studies have gone beyond a solitary assessment of BMI to further char-
acterizing the impact of a more diverse range of body composition measures on mortality 
and other dialysis-related outcomes among patients receiving hemodialysis.
2.2. Methods of body composition assessment
Body composition assessment is one of the objective methods used for nutritional assessment. 
The ability to identify the alteration of muscle or fat mass is absolutely important for the diag-
nosis of PEW and may offer opportunities for timely interventions to retard ongoing catabolic 
process. Because ESRD patients can accumulate significant amount of adiposity concurrently 
with muscle mass depletion [29], it is necessary to quantitate fat and lean mass independently. 
Recently, several tools are available targeting early detection of changes in body composition 
over time. These include anthropometric approaches, rate of creatinine generation or cre-
atinine kinetics, equations to estimate muscle mass, bioimpedance-based evaluation of body 
composition: bioimpedance analysis (BIA) or spectroscopy (BIS), dual X-ray absorptiometry 
(DXA), computerized tomography (CT), magnetic resonance imaging (MRI), and other meth-
odologies that less likely to be used in routine clinical practice such as whole body counting, 
neutron activation analysis, etc.
The human body is divided into two compartments consisting of fat tissue and nonfat tissue 
as shown in (Figure 1).
Body fat is the sum of adipose tissue and fat mass (mainly triglyceride). Adipose tissue is 
composed of collagenous and elastic fibers, fibroblasts, and capillaries. Body fat accumulates 
to around 33% in subcutaneous tissue, to about 4–10% in intramuscular depots, and approxi-
mately 8–12% in visceral thoracic and abdominal area [30]. The nonfat tissue can be defined 
using  more  complicated  terminology  that  sometimes  used  incorrectly  in  the  scientific 
literature: lean body mass (LBM) and fat-free mass (FFM). Lean body mass, may be used 
interchangeably with lean soft tissue, is the sum of total body water, skeletal muscle mass 
(SMM), and also the fat-free part of organs. Fat-free mass is the combination of lean body 
mass and bone mineral component [31]. By virtue of LBM, FFM, and SMM which designate 
as the different tissues of body compartments, choice of methods to determine specific body 
composition should be selected appropriately. For diagnostic purposes, SMM is the repre-
sentative of ideal tissue to study for muscle abnormalities among dialysis population but 
frequently accompanied by higher cost and less portability [32]. Although methods that esti-
mate FFM have greater clinical applicability, lower costs, and ease of use, they tend to have 
lower precision.
To assess body composition in dialysis patients, specific CKD-related factors should be consid-
ered such as hydration status. The accuracy for all methods for estimating body composition 
is affected. Thus, body composition assessment during 15–120 min after dialysis at midweek 
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session, when patients  are most  closely  to  their dry weight,  could  lessen  the  impact of fluid 
overload. This recommendation should be cautious especially with instruments that cannot 
distinguish fluid  between  extra-  and  intracellular  part,  for  example,  single-frequency BIA or 
DXA. Standardized condition and procedure should be repeated when possible to allow repro-
ducibility from time to time [33].
To date, there are several available methods for body composition assessment including 
SMM, LBM, and also FFM as shown in Table 1.
Anthropometric measurements of mid-arm circumference (MAC), mid-arm muscle circumfer-
ence (MAMC), calf circumference, or adductor pollicis muscle thickness are valid for screen-
ing of low muscle mass, whereas triceps skinfold thickness using high-precision calipers 
can estimate subcutaneous fat deposit. Anthropometric research over the previous 40 years 
established that skinfold thickness measured at up to seven sites in various areas of trunk 
and legs by a caliper provides reliable information for estimating body fat and that measure-
ment made at least three sites may be sufficiently informative in most clinical settings. Waist 
circumference (WC) and waist-to-hip ratio (WHR) render a reliable indicator for the amount 
of visceral fat. These relatively simple anthropometric methods have been shown to be good 
proxies of muscle or fat mass, but most of them are subject to inter- and intraobserver vari-
ability, particularly skinfold thickness [34]. Nuclear-based methods (i.e., total body nitrogen 
or body potassium content) are considered the reference methods for body composition, but 
scarce studies were conducted in dialysis patients [35, 36].
Figure 1. Compartments of body composition.
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Modality Methods Body compartment 
assessed
Advantages Disadvantages
1. Anthropometry - MAMC, calf 
circumference, APMT
- SMM Moderate accuracy, 
widely available,  






- Skinfold thickness - Subcutaneous fat






- Various - SMM Usually low cost 
and readily available




- Urinary creatinine 
excretion




by dietary creatine 
and protein 
consumption
- Serum creatinine - LST
4. Bioelectrical 
impedance
- BIA - FFM - Widely available 
and medium cost
- Not a direct 
measure of lean 
mass and affected by 
hydration status
- BIS - LST or SMM - Low inter- 
and intraobserver 
variations, portable 
and less impacted  
by fluid overload
- Relatively high cost 
and cannot be used 
in patients with metal 
implants, pacemakers, 
and limb amputation
5. Whole body 
counting
- Total body potassium - Body cell mass High precision 
and not influenced 
by fluid status




- Total body nitrogen - Body protein store High precision 
and not influenced 
by fluid status




- DXA - LST (total 
and appendicular)
- Readily available 
in most hospitals 
and research centers
- Radiation exposure, 
high cost, affected 
by hydration status 
Orthopedic implants 
can cause artifacts




an estimate of  
SMM









regional (not total) 
estimates of muscle 
size, radiation 
exposure, and high cost
- MRI - Same as CT scan - Same as CT scan - Highest cost, 
estimates regional 
muscle size, 
and cannot be used 
in patients with metal 
products
APMT, adductor pollicis muscle thickness; BIA, bioelectrical impedance analysis; BIS, bioelectrical impedance 
spectroscopy; CT, computerized tomography; DXA, dual X-ray absorptiometry; ESRD, end-stage renal disease; FFM, 
fat-free mass; LST, lean soft tissue; MAMC, mid-arm muscle circumference; MRI, magnetic resonance imaging; SMM, 
skeletal muscle mass.
Table 1. Objective methods for body composition assessment in hemodialysis patients.
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Equations to calculate muscle mass have been originally developed in non-CKD popula-
tion and are often used to estimate appendicular skeletal muscle mass using body weight, 
height, hip circumference, and handgrip strength [37] as well as total muscle mass from BIA 
measurements [38]. One promising study among hemodialysis cohort [39] reported 
the estimation of total body muscle mass using intracellular volume derived from the BIS 
machine as described: SMM (kg) = 9.52 + 0.331 × intracellular volume (L) + 2.77 (if male) + 
0.180 × weight (kg) − 0.113 × age (years). This equation was also validated against muscle 
mass assessment by MRI with R2 value of 0.94, p < 0.001. Previous studies have continually 
attempted to develop equations to estimate FFM among CKD patients based on 24-h urinary 
creatinine excretion, serum creatinine concentration, or the amount of creatinine in dialy-
sate [40, 41]. Even though these equations are in the acceptable agreement with reference 
methods, they have under- or overestimated the true FFM in some circumstances because 
of the absence of consideration on creatinine degradation or daily creatinine excretion [42]. 
Owing to the lack of reference ranges of serum creatinine and urinary creatinine excretion, 
this method would be inappropriate for monitoring of body composition changes.
Imaging techniques have higher precision and accuracy for skeletal muscle mass assessment 
but are time-consuming and expensive. CT and MRI can assess the quantity of the muscle 
in a specific region of  the body in ESRD patients [43]. CT allows the calculation of muscle 
density and the degree of intramuscular fat infiltration as well [44].
Evaluation of body composition by DXA is probably the most popular used imaging technique 
in kidney  researches.  It  emits  two different  energies  of X-ray beams  throughout  the body 
to detect thickness, density, and chemical composition of the tissue. This information is then 
applied through different equations to calculate fat mass, LBM, and bone mineral density by 
assuming a constant hydration status in the derivation of FFM [45]. Therefore, altered fluid 
status can result in over- or underestimation of LBM content by DXA. However, the ability 
to evaluate appendicular skeletal muscle mass (the sum of lean mass of both arms and legs 
but excluding trunk) is the outstanding characteristic of DXA. Recent consensus from expert 
around the world [46–49] currently pays attention on the estimation of appendicular, instead 
of total, muscle mass because it has a higher correlation with muscle strength and physi-
cal function. Additionally, DXA provides precise assessment of fat mass and is sometimes 
regarded as the gold standard. Pitfalls of this machine are high cost, need specialized person-
nel, and may yield limited ability to separate muscle mass from fluid overload.
There are three categories of bioimpedance devices available commercially: single-frequency 
BIA (SF-BIA), multiple-frequency BIA (MF-BIA), and BIS. Regardless of the device specifica-
tion, principles of bioimpedance-based evaluation of body composition involved the admin-
istration of a weak, alternating electrical current at one or more radiofrequencied through 
leads  attached  to  surface  electrodes  for  characterizing  the  conductive  and  nonconductive 
tissue and fluid compartment of the body [50]. The current electrical flow is well conducted 
by water- and electrolyte-rich tissues, for example, blood and muscle, but poorly conducted 
by fat, bone, and air-filled spaces. The reduction of voltage of the current occurs as it passes 
over the body and is detected through the current-sensing electrodes, and then the impedance 
data are recorded by the bioimpedance device [51]. In brief, impedance (Z) is the frequency-
dependent opposition by the conductor (body) to the flow of electrical current. Geometrically, 
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 impedance is the vector composed of resistance (R) and reactance (Xc). Resistance is the opposi-
tion to the flow of current when passing through the body. Reactance is the delay in conduction 
caused by cell membrane, tissue interfaces, and nonionic substances. Capacitance is a function 
of reactance that arises when cell membranes stores a portion of the current for a short time. 
This temporary storage of charge creates a phase shift or “phase angle” described as the ratio 
of the arc tangent of reactance to resistance. At very low (or near zero) frequencies, no conduc-
tion occurs because a higher cell membrane capacitance permits the current to only pass through 
and quantify the extracellular water (ECW). In contrast, at very high frequencies approaching 
infinity, total conduction occurs through cell membranes, therefore allowing the quantification 
of total body water (TBW) [52]. The difference between TBW and ECW determines intracellular 
water (ICW), which theoretically can be used to estimate body cell mass based on the assump-
tion that cells are composed of 73.2% water [53, 54].
By using a single frequency at 50 kHz, SF-BIA can calculate FFM, fat mass, and TBW without dif-
ferentiating ECW from ICW. This machine based on the assumption that the body is a uniform 
conductor with constant geometry is not physiologically accurate. MF-BIA devices typically 
apply the current at one very low frequency (i.e., 50 kHz) and several higher frequencies (i.e., 
50, 10, 200, 500 kHz). Therefore, MF-BIA is able to differentiate between the ECW and ICW com-
partments [55, 56]. Furthermore, MF-BIA can evaluate segmental BIA, to provide more accurate 
whole body estimates, by recognizing the body as having five distinct cylinders (2 arms, 1 trunk, 
2 legs) with different resistivities over which impedances are measured separately.
In general, BIS has more advantages over SF-BIA and MF-BIA in which BIS measures imped-
ance over an entire range of frequencies, does not depend upon population-specific predic-
tion equations to generate whole body volumes and masses, and does not assume that ECW 
and ICW are uniformly distributed [57, 58]. The three-compartment (3C) BIS model (fat mass, 
LBM, and water) incorporates TBW in its assessment, hence controlling for interindividual 
variation in lean tissue hydration and being more accurate for body composition analy-
sis in ESRD population. Using equations based on the 3C model, BIS is the bioimpedance 
method of choice to distinguish lean tissue mass, adipose tissue mass, ICW, and TBW in both 
routine patient care and research [59]. More recently, this technique has largely replaced 
SF-BIA and MF-BIA. As mentioned above, for a more reliable and reproducible assessment 
of body composition, it should be done post dialysis session. Alternatively, if predialysis 
BIS is used instead, there is a recommendation to focus on ICW per kilogram concurrent 
with the interpretation of LBM.
Finally, the appropriateness of each method of body composition assessment should depend 
on availability, practicality, medical purposes, the trained personnel, and most importantly 
patient’ risks and benefits. For clinical routine practice, the method chosen should be simple 
with low risk of complications.
2.3. Association of body adiposity and fat distribution with clinical outcomes
Obesity is increasing worldwide not only in the general population but also ESRD patients. 
In the USA, the incidence and prevalence rate of obesity among those on dialysis is far exceed-
ing in the contemporary estimates in the general population [60]. Apart from BMI, other 
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measures of obesity are skinfold thickness, metrics of central (abdominal) obesity, and per-
centage of body fat. All of which have been reasonably well validated against established gold 
standards and provide estimates of fat mass superior to BMI [61]. Central obesity, recom-
mended by the National Cholesterol Education Program Adult Treatment Panel III (NCEP 
ATP III), was defined as WC of more than 102 (Caucasian) or 90 (Asian) cm in male and 88 
(Caucasian) or 80 (Asian) cm in female [62]. According to the World Health Organization 
(WHO), WHR should not exceed 0.90 in men and 0.85 in women [63]. WC should be mea-
sured over the unclothed abdomen at the midpoint of lower thoracic cage and iliac crest at 
the midpoint of midaxillary line using a nonstretchable standard tape measure. Hip circum-
ference should be assessed at the level of the widest diameter around the buttock according 
to the WHO recommendation [63]. Despite the lack of cut points of percentage of total body 
fat according to the WHO to define obesity, the diagnosis of obesity, as abnormal or excessive 
fat accumulation that may impair health, can be made when body fat exceeds 25% in male 
and 30–35% in female [64].
A study of 30 clinically stable hemodialysis patients indicated that skinfold measurements 
made in triplicate at four sites (biceps, triceps, subscapular, and suprailiac region) by the well-
trained personnel on the opposite site of vascular access as well as BIA performed relatively 
well in which DXA was used as the gold standard with interclass correlation coefficient of 0.94 
and 0.91, respectively [65]. Skinfold thickness measurement at single site (triceps level) also 
demonstrated a good agreement with fat mass content derived by DXA [66]. However, given 
the lack of validation of single-site measurement in CKD population, it is preferable to use skin-
fold measurement made at least three sites, if dedicated well-trained personnel are available, 
rather than single site. The performance of BIA for estimating body fat content has been for-
merly validated against the DXA as a gold standard method. The validity of MF-BIA has been 
specifically assessed in a series of 53 hemodialysis patients with body weight ranging from 35 
to 111 kg. Tetrapolar BIA overestimated total fat mass by only 157 g (95% CI 937–1251 g) versus 
DXA [67]. In another study, SF-BIA obviously provided a satisfactory agreement with the gold 
standard (DXA), among 118 hemodialysis patients [66].
Fat  is  not  uniformly  beneficial  or  that  not  all  fat  is  good.  Measures  of  fat  distribution 
and central obesity such as WC and WHR maintain a direct association with mortality both 
in general population and dialysis patients. Visceral adipose tissue is more closely related 
with metabolic syndrome than is subcutaneous adipose tissue [68, 69]. A strong associa-
tion between WC, WHR, and cardiovascular mortality has been confirmed in a prospective 
cohort of 537 end-stage renal disease patients. The prognostic power of waist circumference 
per 10 cm increase for all-cause (HR 1.23; 95% CI 1.02–1.47, p = 0.03) and cardiovascular mor-
tality (HR 1.37; 95% CI 1.09–1.73, p = 0.006) remained significant after adjustment for other 
cardiovascular comorbidities and traditional and emerging risk factors. WHR was also found 
to be related to all-cause mortality in which a 0.1 unit increase in WHR was significantly asso-
ciated with a 1.24-fold increased risk of all-cause mortality in multivariable Cox regression 
analysis (HR 1.24; 95% CI 1.06–1.46, p < 0.001) but not cardiovascular mortality (adjusted HR 
1.21; 95% CI 0.98–1.50) among dialysis patients [70]. Another study in an Asian hemodialy-
sis cohort found that central obesity (≥90 cm in men and ≥80 cm in women) was predictive 
of increased risk of cardiovascular events (HR 4.91; 95% CI 1.30–18.9, p = 0.02) and all-caused 
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hospitalization (HR 1.83; 95% CI 1.10–3.10, p = 0.03) [71]. These abovementioned data sug-
gested that the distribution of fat mass is important among patients with ESRD and the neg-
ative metabolic consequences of excess visceral fat are preserved despite the association 
of higher BMI with better survival in those populations. Nonetheless, the agreement between 
the absolute changes in WC and visceral fat over time was relatively poor in CKD patients 
[72]. Therefore, WC may not be an inadequate tool for monitoring changes in visceral fat 
in this population. The conicity index, the emerging surrogate of abdominal fat deposition 
that models central obesity as the deviation of body shape from a cylindrical toward a dou-
ble-cone shape (i.e., two cones with a common base at the waist level), predicts mortality 
independently of a series of age, sex, comorbidities, and dialysis vintage in hemodialysis 
patients (HR 1.93; 95% CI 1.06–3.49) [73]. Moreover, as increasing the tertiles of the conicity 
index,  patients were  significantly  older  and  fatter,  reduced handgrip  strength,  and  lower 
serum creatinine. Even though the result of the association of conicity index and hard out-
come is promising, but one should keep in mind that conicity index has never been formally 
validated as a measure of visceral fat against gold standard methods like DXA, CT, or MRI, 
particularly among ESRD patients. Therefore, further confirmation studies in other hemodi-
alysis populations are required to establish the validity of conicity index in this population.
Some studies have reported that a low, rather than a high, body fat mass is an independent 
risk factor of poor survival  in maintenance hemodialysis patients owing to more difficulty 
to cope with the chronic catabolic stress. The summary of studies evaluating the effect of body 
adiposity with various clinical outcomes is shown in Table 2.
A multicenter longitudinal observational study of hemodialysis patients in Europe reported that 
the lowest tertiles of fat tissue index (fat mass normalized by the square of height (kg/m2)), per-
formed 30 minutes before midweek dialysis session using BIS machine, was significantly associ-
ated with lower survival rate during a 12-month follow-up period (HR 3.25; 95% CI 1.33–7.96, 
p = 0.01) after adjustment for traditional and nontraditional risk factors [74]. The authors specu-
lated that the reduction in total body fat may be associated with decreased humoral immunity 
in recognition that adipose tissue can secrete not only inflammatory but also anti-inflammatory 
adipokines such as adiponectin. Therefore, adipose tissues might have some beneficial functions 
related with  energy  storage which may exceed  the harmful  effects  in hemodialysis patients. 
Likewise, percentage of total body fat of less than 15% measured by single-frequency BIA after 
the end of dialysis treatment significantly predicted the overall mortality in 149 prevalent hemo-
dialysis patients [75]. Besides that, hemodialysis patients with percent body fat, measured by 
the use of near-infrared (NIR) interactance via light emission by using NIR spectroscopy, of less 
than 12% had a death hazard ratio four times higher than that of those patients with body fat 
content between 24 and 36% after multivariate adjustment for demographics and surrogates 
of muscle mass and inflammation (HR 4.01; 95% CI 1.61–9.99, p = 0.03) [6]. In a subset of 411 
patients whose fat  loss was reevaluated after a 6-month period, a fat  loss (≤−1%) was signifi-
cantly associated with mortality risk two times that of patients who gained fat (≥1%) after adjust-
ing for covariates (HR 2.06; 95% CI 1.05–4.05, p = 0.04). On the other hand, there was a trend 
toward a significantly worse (or lower) physical health score domain of quality of life, assessed 
by short form of health-related quality of life scoring system (SF-36) in patients with percent 
body fat ≥36% compared to those remaining three categories (<12%, 12–23.9%, and 24–35.9%).
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535 maintenance HD 
patients divided into 
four categories by body 
fat (<12%, 12–23.9%, 
24–35.9%, and ≥36%)
Ranged 
from 41 ± 15 
to 58 ± 14
Total body fat measured by 
near-infrared interactance 
with a coefficient of variation 
of 0.5% (Futrex 6100, 
Gaithersburg, MD)
- Low baseline 
body fat (<12%) 
had a higher death 
HR [4.01; 95% CI 
1.61–9.99, p = 0.003]
- Fat loss (≤−1%) over 
time was associated 
with higher risk 
of death [HR 2.06; 
95% CI 1.05–4.05, p 
= 0.04]
Segall et al. [75] 149 HD patients (55.0% 
men) with mean 
follow-up of 13.5 ± 1.5 
months
53.9 ± 13.7 Percent body fat and phase 
angle by SF-BIA within 30 
minutes after dialysis session
Percent body fat 
<15% and phase 




death risk [adjusted 
HR 4.14; 95% CI 
1.09–15.53, p = 0.036]
Postorino et al. 
[70]
537 ESRD patients in 36 
dialysis units
63 ± 15 WC and WHR by 
anthropometry
- A 10-cm increase 
in WC was associated 
with higher all-cause 
[HR 1.49; 95% CI 
1.26–1.77] and CV 
mortality [HR 1.55; 
95% CI 1.25–1.93]
- A 0.1 unit increase 
in WHR was related 
to overall [HR 1.24; 
95% CI 1.26–1.46] 
but not CV mortality 
[HR 1.21; 95% CI 
0.98–1.50, p = 0.07]
Cordeiro et al. 
[73]
173 HD patients (57.8% 
men) with median 
follow-up of 41 (25–47) 
months
65 (51–74) Conicity index to assess 
abdominal fat accumulation: 
WC (m) divided by 0.109 × 
square root of weight (kg)/
height (cm)
- WC by anthropometry
Mortality 
was increased 
in the highest tertiles 
of conicity index (HR 
6.07; 95% CI 2.51–
14.64) and the highest 
tertiles of WC 
[HR 2.87; 95% CI 
1.29–6.40]
Wu et al. [71] 91 HD patients (54.9% 
men) with dialysis 
vintage of 25 (6–30) 
months
58.7 ± 12.5 WC by anthropometry 
(≥90 cm in men and ≥80 cm 
in women indicate 







[HR 6.25; 95% 
CI 1.65–23.6, p = 
0.007 and adjusted 
HR 4.91; 95% CI 
1.30–18.9, p = 0.02]
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2.4. Magnitude of low muscle mass and sarcopenia with associated outcomes
As the consequences of studies regarding the “obesity paradox,” there is an emerging topic dis-
cussion on the importance of muscle mass over fat mass and vice versa in the nephrology com-
munity. Fat is good but the muscle is better described that fat cells are not metabolically active 
as muscle cells and fat mass can decrease or expand its size depending upon the balance between 
energy intake and expenditure. In contrast, muscle mass is tightly regulated because excess pro-
tein is not stored and the muscle is broken down when proteins or amino acids are needed. 
As the turnover of cellular proteins is estimated to be 1–1.5 kg of the muscle [76, 77], a decrease 
in protein synthesis or an increase in protein degradation can have substantial effects on mus-
cle mass or size. Despite the high prevalence of obesity among ESRD patients, protein energy 
wasting or muscle wasting is not uncommon [78]. The increasing BMI in the dialysis popula-
tion does not exclude concurrent muscle wasting. Excess energy intake concurrent with physi-
cal inactivity, low-grade inflammation, or insulin resistance, all of which are common among 
ESRD patients, may result in muscle mass loss, even in the setting of excess adiposity known 
as “sarcopenic obesity” [79–81]. Recently, sarcopenia is currently defined as a generalized loss 
of skeletal muscle mass combined with reduced muscle strength or physical performance accord-
ing to the European and International Working Group on Sarcopenia in Older People based 
on rationale that muscle strength does not depend solely on muscle mass [46, 48, 82]. As would 
be expected, sarcopenia has been associated with multiple clinical outcomes including physical 
disability, hospitalization, and overall mortality in community-dwelling older adults [83–85]. 
A cross-sectional data from National Health and Nutrition Examination Survey (NHANES) [86] 
demonstrated a higher prevalence of sarcopenia with lower estimated glomerular filtration rate 
suggesting that muscle wasting progresses as renal function deteriorates. Several studies have 
reported a prevalence of sarcopenia or low muscle mass, based on estimates of muscle mass 
indexed to body size and used thresholds for low muscle mass that were based on sex-specific 
norms, among patients with ESRD from 4 to 60% [87–89]. The broad range in the prevalence 
of sarcopenia  is mainly due  to  the  lack of consensus criteria on  the definition of  low muscle 
mass to allow comparison across populations. Frailty, on the other hand, represents a syndrome 
resulting from cumulative deterioration in multiple physiological system, leading to impair 
Authors Study population Age (years) Method of body composition 
assessment
Outcomes
Caetano et al. 
[74]
697 HD patients with 12 
months of follow-up
67 (55.5–76) Fat tissue index (fat tissue/
height2) by midweek pre-
dialysis BIS
The lowest fat tissue 
of index tertiles 
was a significant 
predictor of mortality 
[adjusted HR 3.25; 
95% CI 1.33–7.96, p 
= 0.01]
Data are shown as mean standard deviation, median (interquartile range).
CI, confident interval; CV, cardiovascular; HD, hemodialysis; HR, hazard ratio; MF-BIA, multifrequency bioelectrical 
impedance analysis; SF-BIA, single-frequency bioelectrical impedance analysis; BIS, bioelectrical impedance 
spectroscopy; WC, waist circumference; WHR, waist-hip ratio.
Table 2. Summary of recent studies in the effects of adiposity and outcomes in patients undergoing hemodialysis.
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homeostatic reserve and reduced capacity to withstand stress [90–92]. Therefore, frailty is 
partly overlapped with sarcopenia but sometimes can occur with non-skeletal muscle-related 
conditions.
Body composition  is significantly associated with physical  functioning and quality of  life. 
The longitudinal study in 105 prevalent hemodialysis patients [93] reported that higher 
muscle  area, measured by mid-thigh muscle  area by CT  scan, was  associated with better 
physical function assessed by 6-minute walk distances, whereas higher intra-abdominal fat 
area was inversely correlated with physical performance. Each increment per 1 standard 
deviation of muscle area was also associated with higher physical (HR 3.78; 95% CI 0.73–6.82) 
and mental health component score (HR 3.75; 95% CI 0.44–7.05) of SF-12, a short-form survey 
with questions selected from the SF-36 health survey. In agreement with western communi-
ties, lean tissue index was moderately associated with better physical health assessed by short 
version of WHO quality-of-life scoring system (r = 0.46, p = 0.007) in Asian patients receiving 
hemodialysis [94]. Similarly, other studies examined the associations between body compo-
sition estimated by BIS and frailty. Among approximately 650 hemodialysis patients, frailty 
was defined as having at least three of the following characteristics: weight loss, exhaustion, 
low physical activity, weakness, and slow gait speed. Patients with higher ICV, represent-
ing higher muscle mass, were less likely to be frail, while those with higher fat mass were 
associated with higher odds of frailty [95]. Likewise, the same associations were observed 
among another group of 80 well-characterized hemodialysis participants that performance-
based frailty was associated with smaller muscle size as estimated using cross-sectional area 
of quadriceps muscle by MRI, and this association was of greater magnitude than that of 10 
years of age in multivariate analysis (−30.3 cm2 vs −6.6 cm2, p < 0.001) [96].
Well-preserved amount of muscle mass, as shown by both direct and indirect methods 
of assessments, represents one of the strongest nutritional indicators for survival among 
ESRD population. Report from a large dialysis organization database, transplant-waitlisted 
hemodialysis patients with the highest serum creatinine as a muscle mass surrogate, had sig-
nificantly lower death hazard (HR 0.57; 95% CI 0.49–0.66) compared to the lowest creatinine 
quintiles [27]. Similar associations were observed with serum creatinine change over time. 
Interestingly, de Oliveira and colleagues explored the alternative simple method of anthro-
pometric estimates of adductor pollicis muscle thickness (APMt), performed at the opposite 
hand of vascular access, to predict mortality in hemodialysis patients [97]. APMt was modestly 
correlated with MAMC (r = 0.5, p < 0.001), and the value of APMt ≤ 10.6 mm was significantly 
associated with 3.3 times (95% CI 1.13–9.66) greater risk of hospitalization on the following 
6-month follow-up. At the time of dialysis initiation, nonobese patients with MAMC adequacy 
(more than percentile 90th of normal population from NHANES distribution tables as a refer-
ence) showed that the best survival and reduced MAMC was independent predictor of death 
in incident hemodialysis patients (p = 0.008) [98]. Huang and colleague [99] revealed in a post 
hoc analysis of the Hemodialysis (HEMO) cohort that hemodialysis patients with higher 
MAMC (representing muscle mass) together with higher triceps skinfold thickness (repre-
senting body fatness) showed a consistency toward lower mortality rates during a follow-up 
period of 2.5 years, independently of each other. Another post hoc analysis from the HEMO 
study [100] evaluated the prognostic implications of changes in anthropometric measurement. 
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The authors observed that the decline in MAC (per cm) and sum of the three sites skinfold 
thickness including subscapular, biceps, and triceps (per mm) significantly increased the haz-
ards of infection-related hospitalization, cardiovascular events, and overall death. A prospec-
tive hemodialysis cohort with longer follow-up period of 5 years reported that higher MAMC 
was associated with better SF-36 mental health scale and lower death hazards after adjustment 
for  case-mixed,  malnutrition  inflammatory markers  [101]. In addition, patients with high 
MAMC quartiles combined with either high or low TSF exhibited the greater survival when 
using median values of MAMC and TSF for dichotomizing (death HRs of 0.52 and 0.59, respec-
tively). The authors pointed out that both compartments (muscle and fat) likely have complex 
roles in the maintenance of body homeostasis and equally perform as important nutritional 
parameters among patients receiving hemodialysis. Also, results from the large international 
MONitoring Dialysis Outcomes (MONDO) among over 30,000 participants [102] confirmed 
that both lean and fat tissue masses, as determined by whole body BIS, are important predic-
tors of survival in chronic hemodialysis patients. Mortality rates were significantly higher at 
the lower lean and fat tissue index extreme (HR 3.37; 95% CI 2.94–3.87, p < 0.001). The sum-
mary of studies exploring indicators of muscle mass with outcomes among maintenance 
hemodialysis patients is shown in Table 3.
A relatively large hemodialysis cohort of 960 participants with 54-month follow-up demonstrated 
that patients with muscle wasting, defined as height-normalized lean tissue mass less than 10% 
of normal value by BIS, contributed significantly to the Cox regression model to predict mortal-
ity (HR 1.66; 95% CI 1.10–2.44) compared to those with normal nutrition status [103]. Similarly, 
body composition analysis among 6395 patients from Spain showed that hemodialysis patients 
with lean tissue index lower than percentile 10th had a higher relative risk of death than those 
patients with higher values [104]. Moreover, data from a prospective observation cohort of 299 
hemodialysis population suggested that for every 1 kg gain in lean tissue during the first year 
of dialysis, there was a 7% reduction in all-cause mortality [105].
To address the associations between muscle mass and mortality, some relevant factors such 
as muscle strength or physical performance should be taken into account. Isoyama and cowork-
ers [106] examined the association between low muscle mass and strength with mortality among 
330 Swedish incident dialysis patients. Both low muscle mass (based on appendicular skeletal 
muscle mass by DXA indexed to the square of height) and muscle weakness, determined by 
handgrip dynamometer, were independently associated with higher death rate. However, when 
the two were included in the same analysis, muscle weakness was more strongly associated 
with overall mortality than low muscle mass (HR 1.79; 95% CI 1.09–2.49, p = 0.02 vs 1.17; 95% CI 
0.73–1.87, p = 0.51, respectively). Report from prospective hemodialysis cohort using the United 
State Renal Data System (USRDS) indicated that patients with BIS-derived low muscle mass by 
different indexing methods (height2, percentage of body weight, body surface area, and BMI) 
were associated with higher risk of death in the unadjusted analysis [107]. However, the signifi-
cance of these associations was disappeared after adjustment for covariates. In contrast, functional 
limitations in muscle strength or gait speed were associated with mortality even after adjusting 
for confounders. Taken together, the abovementioned findings underscore the additional poten-
tial contributors to be concerned along with the interpretation of the associations of muscle mass 
Aspects in Dialysis
Authors Study population Age (years) Method of body 
composition assessment
Outcomes
Araujo et al. [98] 344 HD patients (60.5% 
men, 26% diabetes)
50.4 ± 16.0 MAMC and triceps 
skinfold thickness by 
anthropometry
Patients with BMI 
≤25 kg/m2 but having 
MAMC adequacy 
showed the best 
survival. An increase 
in MAMC 
was associated 
with decrease death 
risk by 3% [HR 0.97; 
95% CI 0.96–0.99, p 
= 0.008]
Huang et al. [99] Post hoc analysis of 1709 
HD patients (44% men) 
with mean follow-up 
of 2.5 years
57.7 ± 14 MAMC and triceps 
skinfold thickness by 
anthropometry
The HR per 1 SD 
increase were 0.84 
[95% CI 0.76–0.92] 
for triceps skinfold 
thickness and 0.93 
[95% CI 0.86–1.00] 
for MAMC
Noori et al. [101] 792 maintenance HD 
patients (53% men, 
31% black) with 5-year 
survival follow-up
53 ± 15 MAMC and triceps 
skinfold thickness by 
anthropometry
The highest 
quartiles of MAMC, 
but not triceps 
skinfold thickness, 
were associated 
with death after 
adjusting for case-
mixed and MICS 
(p for trend 
0.04 and 0.15, 
respectively)
Molnar et al. [27] 14,632 wait-listed HD 
patients without KT 
(60% men) with 6-year 
follow-up
52 ± 13 Pre-dialysis serum 
creatinine concentration 
(mg/dL) as a surrogate 
of muscle mass
Patients with >1 mg/
dL decrease of serum 
creatinine had 38% 
higher adjusted 
death risk [HR 1.38; 
95% CI 1.23–1.56, p < 
0.001], whereas those 
patients whose serum 
creatinine increased 
more than 2.4 mg/dL 
reported 13% better 
survival [HR 0.87; 
95% CI 0.75–0.99, p = 
0.045].
de Oliveira et al. [97] 143 HD patients (58% 
male)
52.2 ± 16.6 APMt measurement 
was performed using 
a Lange caliper 





risk within 6 months 
[HR 3.3; 95% CI 1.13–
9.66, p = 0.03] but not 
associated with higher 
risk of death within 6 
and 12 months
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Authors Study population Age (years) Method of body 
composition assessment
Outcomes
Su et al. [100] Post hoc analysis of 1846 
HD patients (43.6% men) 
with mean follow-up 
of 2.8 ± 1.8 years
58 MAC and sum of skinfold 
thickness (subscapular, 
biceps, and triceps) 
by anthropometry 
to the nearest 0.1 cm
- Among participants 
with BMI≤25 kg/
m2, decline in MAC 
per 1 cm, but not 
skinfold thickness, 
was associated 
with higher mortality 
[HR 1.14; 95% CI 
1.09–1.19, p < 0.001]
- Baseline MAC 
(per 1 cm lesser) 
was associated 
with higher cardiac 
hospitalization 
[HR 1.07; 95% CI 
1.02–1.11, p = 0.002] 
and infection-related 
death [HR 1.21; 95% 
CI 1.10–1.34, p < 0.001]
Yongsiri et al. [94] 34 HD patients (47.1% 
men)
61.1 ± 15.5 Lean and fat tissue 
(indexed to height2) 
was obtained by BIS after 
dialysis session
Among HD patients, 
there was a positive 
correlation between 
lean, but not 
fat, tissue index 
and physical health 
(r = 0.46, p = 0.007)
Isoyama et al. [106] 330 incident HD 
patients (61.5% men) 
with mean follow-up 
of 29 (1–48) months
53 ± 13 - ASM measurement by 
DXA and cutoffs for low 




- Handgrip strength 
cutoffs were <30 kg in men 
and <20 kg in women
- Muscle mass 
(per 1 SD increase) 
was associated 
with lower mortality 
[HR 0.21; 95% CI 
0.06–0.73, p = 0.01]
- Low muscle mass 
was not significantly 
associated with higher 
mortality [HR 1.17; 
95% CI 0.73–1.87, 
p = 0.51] compared 
with appropriate 
muscle mass
- Low muscle strength 
was associated 
with increased risk 
of death [HR 1.79; 95% 
CI 1.09–2.94, p = 0.02]
Keane et al. [105] 299 HD patients at six 
dialysis units (62% men, 
42% diabetes)
63 ± 15 Lean and fat tissue index 
was obtained by BIS 
(indexed to height2)
A 7% reduction 
in mortality for every 
1 kg gain in lean 
tissue during 1 year 
after dialysis initiation 
[HR 0.93; 95% CI 
0.99–0.98, p = 0.01]
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and survival among patients undergoing hemodialysis because risk factors for the loss of muscle 
mass may not be similar to those for the loss of muscle functionality.
2.5. Strategies to preserve body composition in patients receiving maintenance 
hemodialysis
Intervention to preserve muscle mass and reduce excess body fat is an ultimate goal 
for improving outcomes among ESRD population. However, a major limitation in the devel-
opment of effective therapies against muscle loss is the imprecision of the available methods 
Authors Study population Age (years) Method of body 
composition assessment
Outcomes
Castellano et al. 
[104]
6395 HD patients (62.7% 
men, 28.5% diabetes)
67.6 ± 14.7 Lean and fat tissue 
(indexed to height2) 
was obtained by BIS 
before dialysis session
Lean tissue index 
lower than percentile 
10th had a higher 
relative risk of death 
[HR 1.57; 95% CI 
1.13–2.20, p < 0.05]
Kittiskulnam et al. 
[107]
645 prevalent HD 
patients (58.6% men, 
61.5% black, 43.9% 
diabetes) with mean 
follow-up of 1.9 (0.1–3.2) 
years
56.7 ± 14.5 - TBMM was derived 
by pre-dialysis BIS 
and indexed to height2 





of young adults using 
NHANES by each 
indexing strategy




- Slow walking speed 
was defined as ≤0.8 m/s
- Low muscle mass by 





with normal muscle 
mass, but these 




- Low grip strength 
was associated 
with increased risk 
of death [HR 1.68; 95% 
CI 1.01–2.79, p = 0.04]
- Slow walking 
speed was associated 
with higher mortality 
risk [HR 2.25; 95% CI 
1.36–3.74, p = 0.002]
Data are shown as mean standard deviation, median (interquartile range).
APMt, adductor pollicis muscle thickness; ASM, appendicular skeletal muscle; BIS, bioelectrical impedance 
spectroscopy; BMI, body mass  index; BSA, body surface area; CI,  confident  interval; CV,  cardiovascular; DXA, dual 
X-ray absorptiometry; HD, hemodialysis; HR, hazard ratio; KT, kidney transplantation; MAC, mid-arm circumference; 
MAMC, mid-arm muscle circumference; MICS, malnutrition inflammation cachexia syndrome; MF-BIA, multifrequency 
bioelectrical impedance analysis; NHANES, National Health and Nutrition Examination Survey; SF-BIA, single-
frequency bioelectrical impedance analysis; TBMM, total body muscle mass.
Table 3. Selected articles evaluating low muscle mass, sarcopenia, and sarcopenic obesity with outcomes among 
maintenance hemodialysis patients.
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to assess changes in muscle mass during intervention. One alternative approach is serum 
biomarkers to determine the anabolic and catabolic balance within muscular structure. 
For example, serum creatinine may be a suitable surrogate of muscle mass in ESRD patients 
with no residual renal function and the novel biomarker N-terminal propeptide of type III 
procollagen (P3NP) that plays an important step during collagen synthesis [108]. At present, 
prevention and treatment of uremic muscle wasting should be initially based on optimal 
nutrition support and correction of acidosis [109, 110]. Other established therapies for pre-
vention of muscle loss are physical exercise and supraphysiologic dose of anabolic steroid.
Recent observational data uncovered  the benefit of  increased physical  activity with higher 
estimated muscle mass. In hemodialysis patients, aerobic exercise was positively associ-
ated with skeletal muscle mass volumes after adjustment for age, sex, and dialysis vintage 
[111]. Data from randomized controlled trials have demonstrated that intradialytic resistance 
exercise training can improve muscle volume and enhance muscle strength [112] or physi-
cal performance [113, 114] among hemodialysis patients. The use of resistance exercise com-
bined with anabolic steroid (nandrolone decanoate) has been shown to increase muscle mass 
and decrease body fat among patients with ESRD [115, 116]. Furthermore, an oral andro-
gen,  oxymetholone,  has  significantly  shown  an  anabolic  effect  to  increase  amount  of  FFM 
and handgrip strength, but this drug raised concerns about liver toxicity [117], suggesting that 
intramuscularly or transdermally administered androgens are better choices for further stud-
ies in ESRD population.
Another treatment strategy of preventing muscle mass loss includes active vitamin D admin-
istration [118]. Hemodialysis patients receiving either alfacalcidol or calcitriol experienced 
increase in the total amount of muscle mass assessed by BIA and a favorable effect on main-
taining in physical functioning. Recombinant human growth hormone (rhGH) adminis-
tered at a pharmacological dose may simultaneously improve net muscle protein synthesis 
and decrease muscle protein breakdown [119, 120]. Nonetheless, analysis from hemodialysis 
participants in a large GH supplementation trial suggested that rhGH was linked to adverse 
cardiovascular disease risk [121]. Currently, rhGH is thus not recommended to treat muscle 
wasting among CKD patients. Lastly, targeting pro-inflammatory cytokines such as interleu-
kin (IL)-1, IL-6, and tumor necrotic factor as well as manipulation of myogenic stem (satellite) 
cell or transforming growth factor-β superfamily members are all the potential future treat-
ments to preserve body composition changes [122].
In conclusion, body composition is usually altered among patients undergoing main-
tenance  hemodialysis.  Sarcopenia,  sometimes  might  occur  in  the  setting  of  obesity,  is 
a significant predictor of mortality outcome among patients receiving maintenance hemo-
dialysis. Despite the positive association of higher BMI with greater survival in hemo-
dialysis patients, visceral adiposity is associated with adverse cardiovascular outcomes. 
Additionally, changes in body composition over time might be informative as a predictor 
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